Suchergebnisse - "Pan, Daniel"

PubPharm (4)

1

Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK : eight-month analyses of the COV-BOOST trial

enthalten in: The Journal of infection | 2023

von Liu, X. | Munro, A. | Wright, A. | +59

2

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST) : a multicentre, blinded, phase 2, randomised trial

enthalten in: The Lancet. Infectious diseases | 2022

von Munro, A. | Feng, S. | Janani, L. | +153

CommentIn: Lancet Infect Dis. 2022 Aug;22(8):1092-1093. - PMID 35550263

3

Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK : Three month analyses of the COV-BOOST trial

enthalten in: The Journal of infection | 2022

von Liu, X. | Munro, A. | Feng, S. | +56

CommentIn: J Infect. 2023 Feb;86(2):154-225. - PMID 36509358

4

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST) : a blinded, multicentre, randomised, controlled, phase 2 trial

enthalten in: Lancet (London, England) | 2021

von Munro, A. | Janani, L. | Cornelius, V. | +152

ErratumIn: Lancet. 2021 Dec 18;398(10318):2246. - PMID 34922669

1
[1]